GSTP1 DNA Methylation and Expression Status in Prostate Cancer Treatment
Author Information
Author(s): Chiam Karen, Centenera Margaret M., Butler Lisa M., Tilley Wayne D., Bianco-Miotto Tina, Agoulnik Irina
Primary Institution: Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide
Hypothesis
Is GSTP1 a useful marker of DNMTi treatment efficacy in prostate cancer?
Conclusion
GSTP1 DNA methylation and protein expression status are good indicators of DNMTi efficacy in prostate cancer cells.
Supporting Evidence
- Daily treatment with 5-aza-CdR significantly suppressed cell proliferation.
- GSTP1 protein re-expression was observed at doses associated with cell death.
- Zebularine required much higher doses to achieve similar effects as 5-aza-CdR.
Takeaway
This study found that a daily low dose of a drug called 5-aza-CdR can help treat prostate cancer by changing the DNA of cancer cells, making it a better option than a single high dose.
Methodology
LNCaP prostate cancer cells were treated with varying doses of 5-aza-CdR and Zebularine, and cell viability and DNA methylation status were assessed.
Limitations
The study primarily focused on in vitro results, which may not fully translate to clinical outcomes.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website